# Daguan Wang

> Daguan Wang is a Series B investor at Yonjin Venture (Cambridge) backing Biotechnology and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Yonjin Venture](https://shizune.co/investors/profile/yonjin-venture)
- Location: Cambridge, United States
- Total investments: 4
- Last investment: Mar 2021
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/daguang-wang-47b6a6a

Daguan Wang is a Series B investor at Yonjin Venture in Cambridge focused on Biotechnology and Medical. Daguang Wang is the Managing Director at Yonjin Venture. Before that, he was the Director of Global BD and External Innovation Neuroscience of Sanofi and the Business Development Consultant at MyGal.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 100% |
| Medical | 3 | 75% |
| Health Care | 3 | 75% |
| Biopharma | 2 | 50% |
| Therapeutics | 2 | 50% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 50% |
| Series A | 1 | 25% |
| Series C | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 75% |
| Israel | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| OncoResponse | OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer. | $40.6M | Series C | Mar 31, 2021 |  |
| Regenacy Pharmaceuticals | Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies. |  | Series A | Mar 25, 2020 |  |
| Metabomed | Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment. | $12.5M | Series B | Dec 19, 2019 |  |
| Frequency Therapeutics | Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts. | $42M | Series B | Jan 07, 2019 |  |

4 of 4 investments shown.

## Co-investors
- [Cobro Ventures](https://shizune.co/investors/profile/cobro-ventures) — VC Fund, 2 deals together
- [Rivas Capital](https://shizune.co/investors/profile/rivas-capital) — VC Fund, 2 deals together
- [Taiwania Capital Management Corporation](https://shizune.co/investors/profile/taiwania-capital) — VC Fund, 2 deals together
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 1 deal together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 1 deal together

## About Yonjin Venture

VC Fund · Cambridge, United States

Yonjin Venture is an investment firm specializing in investing in early and mid-stage life science companies.It focuses on the innovative technologies in therapeutics, diagnostics, and medical devices. The firm is a sub-organization of Yongjin Group and the sister firm of Yonghua Capital.The Cambridge, Massachusetts-based firm was establishedin 2018.

5 contacts available at Yonjin Venture.

| Name | Title | Profile |
| --- | --- | --- |
| Chong Wang | Executive Director | https://shizune.co/investors/profile/chong-wang-9245 |
| Daguan Wang | Managing Director | https://shizune.co/investors/profile/daguang-wang |
| Fanbo Meng | Executive Director | https://shizune.co/investors/profile/fanbo-meng-816b |
| Gary Yang | Partner | https://shizune.co/investors/profile/gary-yang-8f84 |
| Qiong Ye | Vice President | https://shizune.co/investors/profile/qiong-ye |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Daguan Wang invest in?

Daguan Wang invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Daguan Wang last invest?

The most recent investment recorded for Daguan Wang closed in Mar 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co